Scopolamine - GT Biopharma

Drug Profile

Scopolamine - GT Biopharma

Alternative Names: GTP-011; Repurposed scopolamine - GT Biopharma

Latest Information Update: 18 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Georgetown Translational Pharmaceuticals
  • Developer GT Biopharma
  • Class Antiemetics; Antispasmodics; Hypnosedatives; Mydriatics; Small molecules; Tropanes
  • Mechanism of Action Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Motion sickness

Most Recent Events

  • 11 Sep 2017 Georgetown Translational Pharmaceuticals has been acquired and merged into GT Biopharma
  • 17 Aug 2017 Chemical structure information added
  • 08 Aug 2017 Georgetown Translational Pharmaceuticals announces intention to submit an IND application to US FDA for Motion sickness in the last quarter of 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top